The global burden of chronic kidney disease
Chronic kidney disease (CKD) is a non-communicable disease usually caused by diabetes and hypertension. 1 Cardiovascular disease is the major cause of the early morbidity and mortality sustained by patients with CKD. The severity of CKD can be quantified by a low serum creatinine-based estimated glomerular filtration rate (eGFR), which indicates excretory kidney function, and raised urinary albumin measured by the urinary albumin-to-creatinine ratio (ACR), which is a marker of kidney damage. 2 The Kidney Disease: Improving Global Outcomes classification system for staging CKD is based on eGFR and ACR and is widely used in clinical practice.
In The Lancet, the Global Burden of Disease (GBD) Chronic Kidney Disease Collaboration report a comprehensive analysis of the global prevalence and burden of CKD. 3 The researchers used established GBD methodology in their analysis of data for 1990-2017 from 195 countries. Complex statistical modelling was applied to minimise uncertainty in primary data, and predictive covariates and geographical proximity estimates were used to maximise accuracy for countries with limited primary data.
In 2017, the global prevalence of CKD was 9·1% (95% uncertainty interval [UI] 8·5 to 9·8), which is roughly 700 million cases. Since 1990, the prevalence of CKD has increased by 29·3% (26·4 to 32·6), but agestandardised prevalence has remained unchanged during this period (1·2%, -1·1 to 3·5). A substantial increase was noted in age-standardised incidence of end-stage kidney disease (ESKD) treated by renal replacement therapy, with dialysis and kidney transplantation increasing by 43·1% (95% UI 40·5 to 45·8) and 34·4% (29·7 to 38·9), respectively. The global increase in mortality from CKD since 1990 was 41·5% (95% UI 35·2 to 46·5), such that mortality from CKD, and cardiovascular disease deaths attributable to impaired kidney function (a term used to describe a low eGFR or elevated ACR without treatment by renal replacement therapy) caused 4·6% (4·3 to 5·0) of global deaths in 2017, making CKD the 12th leading cause of death globally in 2017, an increase from 17th in 1990. Age-standardised mortality remained unchanged, with a 2·8% change (95% UI -1·5 to 6·3) from 1990 to 2017.
Large between-region and between-country variations were noted in deaths from CKD; for example, in central Latin America, central Asia, and high-income North America, CKD mortality increased by around 60%. In central and Andean Latin America, CKD was, respectively, the second and fifth ranked cause of death in 2017. Overall, these GBD data are a stark confirmation that the global burden of CKD is increasingly carried by countries in low and middle Socio-demographic Index (SDI) quintiles.
The differential changes in prevalence of and mortality from CKD are likely to be multifactorial. Some countries showed increases compared with neighbouring countries with similar demographics, indicating increased recognition and recording of CKD and mortality from this disease. Survival is also extended (with population ageing) in countries in lower SDI quintiles, with an epidemiological shift in mortality from communicable diseases to non-communicable diseases, with major increases in the prevalence of diabetes and hypertension. 4, 5 In some regions, changes might also be seen in disease epidemiology; for example, in some Latin American countries, CKD of unknown cause (eg, mesoamerican nephropathy) is prevalent. 6 Disability-associated life-years (DALYs) caused by CKD, or cardiovascular disease and gout attributable to impaired kidney function, varied more than 15-fold between countries. Generally, regions and countries within the lower SDI quintiles sustained the highest rates of DALYs. Years living with disability (YLDs) accounted for only 20·3% (95% UI 15·9-24·6) of the total CKD DALYs, probably because most patients had mild-to-moderate CKD (ie, stages 1-3), a level of disease at which specific functional impairment is uncommon.
These GBD data demand careful reading by policy makers and clinicians. CKD-attributable morbidity and mortality follow the paradigm for chronic disease, whereby access to identification and management is dependent on income and geography. Patients living in countries in low and middle SDI quintiles who do not die during progression of CKD will typically die within months when they reach ESKD, because renal replacement therapy is not available or dialysis is inadequate. Kidney transplantation, the best health-preserving and economic treatment for ESKD, only accounts for a fifth of renal replacement therapy, and programmes are underdeveloped in most countries.
The global age-standardised mortality rate for CKD is not declining, unlike those for other important noncommunicable diseases. 7 Interventions to slow kidney disease progression require early testing of people at risk by measurement of eGFR and ACR. Even in highincome countries, ACR testing is generally not done, 8 despite being a major independent risk factor for CKD progression and cardiovascular disease events. 9 Inexpensive interventions for diabetes, hypertension, and CKD can have a substantial effect on clinical and societal outcomes. 10 Supporting countries to develop sustainable and affordable health-care infrastructure for CKD and other non-communicable diseases, from public health legislation to population-based identification and management programmes, is a global priority. 11, 12 PC declares honoraria for educational seminars from NAPP Pharmaceuticals, outside of the area of work commented on here. L-AF declares no competing interests.
